Jason Napodano Blog | Want Fully Independent Biopharma Stock Research? | Talkmarkets

Want Fully Independent Biopharma Stock Research?

Date: Wednesday, May 17, 2017 9:33 PM EDT

Hello, TalkMarkets Community!

I'd like to introduce you to Bio5C, my new subscription-based biotech and specialty pharma equity research service. At Bio5C, I analyze stocks using my "5 C's of Biotech Investing™" methodology. My 5 C's are Cash, Catalyst, Charisma, Capital Structure, and Credibility. These are the five most important attributes I've found that lead to strong stock price performance over the short- and long-term.

At Bio5C, I've scored over 90 company using my 5 C's methodology, rating each category on a scale of 1-5, with 1 representing an "F" and 5 representing an "A" on the grade school scale. The Total 5C score is then ranked with the concept that the highest scoring names should be bought and the lowest scoring names should be avoided.

Bio5C is an excellent starting point for idea generation in the biopharma sector. Our model highlights potential winners and can help you identify red flags or potential short ideas. The research is 100% independent and I fully disclosure my positions in each report I write and on my Twitter. I encourage you to check out www.Bio5C.com for additional information.

Subscribers to the service get the following:

1) Full access to the 5C Model, which includes six tabs (one that shows the individual 5C score for all 90 stocks, one that shows the historical score as it changes monthly, one that ranks all 90 names by total score, one that shows the cash position and projected burn rate, one that shows the capital structure and ownership, and one that shows upcoming catalysts). The 5C Model page is updated daily as companies in the universe provide material updates.

2) Full access to all the research Notes I produce on the "most interesting" long and short ideas each month. I currently have 24 reports available for subscribers. One report - Axsome Therapeutics - is available for free so you can see what you are getting with your subscription. The Notes are designed to be short and concise, providing a starting point for further due diligence and analysis.

1 2
View single page >> |
Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.


Leave a comment to automatically be entered into our contest to win a free Echo Show.